Sonoma Pharmaceuticals 

€0
22
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.74
-0.53
-0.32
-0.11
Expected EPS
-0.2058168
Actual EPS
N/A

Financials

-24.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
26.5MRevenue
-6.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow O8Z.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson offers a wide range of healthcare products that compete with Sonoma Pharmaceuticals' dermatological and wound care products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and markets drugs and vaccines, including those for infections and inflammations, competing with Sonoma's infection prevention products.
Merck
MRK
Mkt Cap298.84B
Merck produces pharmaceuticals that directly compete with Sonoma Pharmaceuticals in the areas of infection and wound care.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie has a strong portfolio in dermatology, directly competing with Sonoma Pharmaceuticals' skin health products.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline has a diverse range of healthcare products, including those for skin health and infection control, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb offers various healthcare products that compete in the therapeutic areas covered by Sonoma Pharmaceuticals.
Novartis
NVS
Mkt Cap297.32B
Novartis provides innovative healthcare solutions, including dermatology and wound care products, competing with Sonoma Pharmaceuticals.
AMGEN
AMGN
Mkt Cap187.56B
Amgen focuses on human therapeutics, including treatments for skin conditions and infections, competing with Sonoma's product range.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals specializes in biopharmaceuticals, competing in the dermatology and infection prevention market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries offers generic and specialty medicines, including dermatological products, competing with Sonoma Pharmaceuticals.

About

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Show more...
CEO
ISIN
US83558L3033
WKN
000A40M9J

Listings

0 Comments

Share your thoughts

FAQ

What is Sonoma Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sonoma Pharmaceuticals stocks are traded under the ticker O8Z.F.
When is the next Sonoma Pharmaceuticals earnings date?
Sonoma Pharmaceuticals is going to release the next earnings report on July 15, 2026.
What were Sonoma Pharmaceuticals earnings last quarter?
O8Z.F earnings for the last quarter are -0.3 EUR per share, whereas the estimation was -0.24 EUR resulting in a -21.23% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sonoma Pharmaceuticals revenue for the last year?
Sonoma Pharmaceuticals revenue for the last year amounts to 26.5M EUR.
What is Sonoma Pharmaceuticals net income for the last year?
O8Z.F net income for the last year is -6.42M EUR.
When did Sonoma Pharmaceuticals complete a stock split?
The last stock split for Sonoma Pharmaceuticals was on August 30, 2024 with a ratio of 1:20.